C4 Therapeutics
CCCC
115 hedge funds and large institutions have $281M invested in C4 Therapeutics in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 34 reducing their positions, and 25 closing their positions.
198% more call options, than puts
Call options by funds: $3.53M | Put options by funds: $1.18M
40% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 25
8% more funds holding
Funds holding: 106 → 115 (+9)
3.62% more ownership
Funds ownership: 84.87% → 88.49% (+3.6%)
6% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 34
41% less capital invested
Capital invested by funds: $476M → $281M (-$194M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.7M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$19.4M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$9.5M |
| 4 |
O
OrbiMed
New York
|
+$9.02M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$24.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.2M |
| 3 |
Citigroup
New York
|
-$4.41M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$4.37M |
| 5 |
Rafferty Asset Management
New York
|
-$3.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCM
126
Graham Capital Management
Rowayton,
Connecticut
| – | -$388K | -47,449 | Closed |
|
127
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$260K | -41,445 | Closed |
|
|
DM
128
Deerfield Management
New York
| – | -$234K | -28,590 | Closed |
|
129
Walleye Trading
New York
| – | -$203K | -24,794 | Closed |
|
|
RA
130
Royce & Associates
New York
| – | -$193K | -23,604 | Closed |
|
131
SG Americas Securities
New York
| – | -$183K | -22,368 | Closed |
|
|
PCMH
132
Polymer Capital Management (HK)
Hong Kong
| – | -$179K | -21,906 | Closed |
|
|
LP
133
LMR Partners
London,
United Kingdom
| – | -$160K | -19,563 | Closed |
|
|
OQS
134
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$150K | -18,317 | Closed |
|
|
ET
135
Entropy Technologies
New York
| – | -$126K | -15,391 | Closed |
|
136
Principal Financial Group
Des Moines,
Iowa
| – | -$108K | -13,238 | Closed |
|
|
QT
137
Quantbot Technologies
New York
| – | -$84.2K | -10,300 | Closed |
|
138
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$33 | -4,009 | Closed |
|
139
US Bancorp
Minneapolis,
Minnesota
| – | -$319 | -39 | Closed |
|
CCCC Hedge Fund Activity: Q2 2024 in Review
115 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2024, worth a combined $281M — down 41% from $476M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CCCC positions and 25 closed out — a net gain of 10 holders — while 32 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $21.7M. The largest seller was State Street, cutting an estimated $24.8M.
- 115 institutional investors held C4 Therapeutics (CCCC) as of Q2 2024, up from 106 in Q1 2024.
- Funds reported $281M of C4 Therapeutics stock for Q2 2024, down 41% quarter-over-quarter.
- 35 funds opened new C4 Therapeutics positions in Q2 2024 and 25 closed out, a net change of +10 holders.
- The largest C4 Therapeutics buyer in Q2 2024 was BlackRock, an estimated $21.7M added.
- The largest C4 Therapeutics seller in Q2 2024 was State Street, an estimated $24.8M sold.
Based on aggregated 13F filings for Q2 2024.